The pituitary V3 vasopressin receptor and the ectopic corticotropin syndrome

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 2, 1996, Pages 125-131

  De Keyzer, Yves ^a   Clauser, Eric ^a   Bertagna, Xavier ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001659456     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199604000-00009     Document Type: Article

References (59)

1. Orth DN: Cushing's syndrome. N Engl J Med 1995, 332:791-803. The most recent update on all aspects of Cushing's syndrome (pathophysiology, diagnosis, and treatment). Orth distinguishes the acute and the chronic ectopic corticotropin syndrome, ie, the classic and the occult forms.
2. Brown WH: A case of pluriglandular syndrome: "diabetes of bearded women." Lancet 1928, 2:1022-1023.
3. Meador CK, Liddle GW, Island DP, Nicholson WE, Lucas CP, Nuckton JG, Luetscher JA: Cause of Cushing's syndrome in patients with tumors arising from "nonendocrine" tissue. J Clin Endocrinol Metab 1962, 22:6893-6703.
4. Findling JW, Tyrrel JB: Occult ectopic secretion of corticotropin. Arch Intern Med 1986, 146:929-933.
5. Liddle GW, Nicholson WE, Island DP, Orth DN, Abe L, Lowder SC: Clinical and laboratory studies of ectopic humoral syndromes. Rec Prog Horm Res 1969, 25:283-314.
6. Vieau D, Linard CG, Mbikay M, Lenne F, Chretien M, Luton JP, Bertagna X: Expression of the neuroendocrine cell marker 7B2 in human ACTH secreting tumors. Clin Endocrinol 1992, 36:597-603.
7. De Keyzer Y, Vieau D, Picon A, Bertagna X: Molecular aspects of the ectopic ACTH syndrome. Endocr Rel Cancer 1996, in press. This review updates the molecular variants generated by POMC gene expression in the ectopic ACTH syndromes: the various forms of POMC mRNAs and the altered products of POMC processing. It also reviews our current knowledge of transcription factors acting on the rat POMC gene in AtT-20 cells. It shows the first data obtained by transfection of the human POMC gene promoter in the POMC-producing human SCCL cell line DMS-79.
8. De Keyzer Y, Auzan C, Lenne F, Beldjord C, Thibonnier M, Bertagna X, Clauser E: Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 1994, 356:215-220. Describes the cloning and the structure of the human V3 vasopressin receptor. The pharmacologic characteristics of the receptor are studied in detail in transfected COS cells. A phylogenetic tree is shown that also led to the preference of the V3 designation over the V1b.
9. Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H: Molecular cloning and functional expression of a cDNA encoding in human V1b vasopressin receptor. J Biol Chem 1994, 269:27088-27092.
10. Saito M, Sugimoto T, Tahara A, Kawashima H: Molecular cloning and characterization of a rat V1b vasopressin receptor: evidence for its expression in extra-pituitary tissues. Biochem Biophys Res Commun 1995, 221:751-757.
11. Lolait SJ, O'Carroll A-M, Mahan LC, Felder CC, Button DC, Young Scott W III, Mezey E, Brownstein MJ: Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A 1995, 92:6783-6787. The cloning of the rat V1b (V3) vasopressin receptor. A large tissue distribution study is performed with the highly sensitive RT-PCR technique. The V1b (V3) receptor mRNA can be detected in many brain areas including the hypothalamus, and in some peripheral organs such as the heart, lung, adrenals, and kidney. Yet all these tissues have extremely low V3 receptor signals compared with the pituitary.
12. Wajchenberg BL, Mendonca BB, Liberman B, Pereira MA, Carneiro PC, Wakamatsu A, Kirschner MA: Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 1994, 15:752-787. The most recent review on ectopic ACTH syndrome. This is a vast and eclectic work that gives much information (237 references) yet says nothing about vasopressin. A special part is devoted to the occult ectopic ACTH syndrome.
13. Mason AMS, Racliffe JG, Buckle RM, Mason AS: ACTH secretion by bronchial carcinoid tumours. Clin Endocrinol 1972, 1:3-25.
14. Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM: Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol 1986, 24:699-713.
15. Nieman LK, Chrousos GP, Oldfield EH, Avgerinos PC, Cutler GB, Loriaux DL: The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med 1986, 105:862-867.
16. Strott CA, Nugent CA, Tyler FH: Cushing's syndrome caused by bronchial adenoma. Am J Med 1968, 44:97-104.
17. Florkowski CM, Wittert GA, Lewis JG, Donald RA, Espiner EA: Glucocorticoid responsive ACTH secreting bronchial carcinoid tumors contain high concentrations of glucocorticoid receptors. Clin Endocrinol 1994, 40:269-274.
18. Malchoff CD, Orth DN, Abboud C, Carney JA, Pairolero PC, Carey RM: Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988, 84:760-764.
19. Suda T, Tozawa F, Dobashi I, Horiba N, Ohmori N, Yamakado M: Corticotropin-releasing hormone, proopiomelanocortin, and glucocorticoid receptor gene expression in adrenocorticotropin-producing tumors in vitro. J Clin Invest 1993, 92:2790-2795. This study examines the in vivo and in vitro responses to various secretagogues of 10 patients with ectopic ACTH syndrome. It shows that the three bronchial carcinoids of the series responded in vitro to vasopressin with increased ACTH release. The same tumors contained functional glucocorticoid receptors as assessed by in vitro studies and Northern blot analysis. No pharmacologic study was performed to further characterize the subtype of vasopressin receptor. This paper provides interesting molecular clues to explain the pituitary-like behavior of ACTH-secreting bronchial carcinoids.
20. Vieau D, Rojas-Miranda A, Verley JM, Lenne F, Bertagna X: The secretory granule peptides 7B2 and CCB are sensitive biochemical markers of neuro-endocrine bronchial tumors in man. Clin Endocrinol 1991, 35:319-325.
21. Scopsi L, Gullo M, Rilke F, Martin S, Steiner DF: Proprotein convertases (PC1/PC3 and PC2) In normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. J Clin Endocrinol Metab 1995, 80:294-301. The long-sought and recently cloned prohormone convertases are now studied in human tumors. In contrast with SCCLs, carcinoids almost invariably contain both PC1 and PC2.
22. Vieau D, Seidah NG, Chrétien M, Bertagna X: Expression of the prohormone convertase PC2 correlates with the presence of CLIP in human ACTH secreting tumors. J Clin Endocrinol Metab 1994, 79:1503-1509.
23. Creemers J, Roebroek A, Van de Ven W: Expression in human lung tumor cells of the proprotein processing enzyme PC1/PC3: cloning and primary sequence of a 5Kb cDNA. FEBS Lett 1992, 300:82-88.
24. Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler GBJ, Loriaux DL: Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991, 325:897-905.
25. Findling JW, Kehoe ME, Shaker JL, Raff H: Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. J Clin Endocrinol Metab 1991, 73:408-413.
26. Jard S: Vasopressin receptors. Front Horm Res 1985, 13:89-104.
27. Antoni F: Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology 1984, 39:186-188.
28. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Mattera-Berti L, Clauser E: Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 1994, 269:3304-3310.
29. Morel A, O'Carroll AM, Brownstein MJ, Lolait SJ: Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 1992, 356:523-526.
30. Birnbaumer M, Seibold A, Gilbert S, Ishido J, Barberis C, Antaramian A, Brabet P, Rosenthal W: Molecular cloning of the receptor of human antidiuretic hormone. Nature 1992, 357:333-335.
31. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ: Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992, 357:336-339.
32. Kimura T, Tanazawa O, Mori K, Brownstein MJ, Okayama H: Structure and expression of a human oxytocin receptor. Nature 1992, 356:526-529.
33. Mahlmann S, Meyerhof W, Hausmann H, Heierhorst J, Schönrock C, Zwiers H, Lederis K, Richter D: Structure, function, and phylogeny of [Arg8] vasotocin receptors from teleost fish and toad. Proc Natl Acad Sci U S A 1994, 91:1342-1345.
34. Rousseau-Merck MF, René P, Derré J, Bienvenu J, Berger R, De Keyzer Y: Chromosomal localization of the human V3 pituitary vasopressin receptor gene to 1q32. Genomics 1995, 30:405-406.
35. Antoni FA: Receptors mediating the CRH effects of vasopressin and oxytocin. Ann N Y Acad Sci 1988, 512:195-204.
36. Jard S, Gaillard G, Guillon G, Marie J, Schoenenberg P, Muller AF, Manning M, Sawyer WH: Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol Pharmacol 1986, 30:171-177.
37. Du Pasquier D, Loup F, Dubois-Dauphin M, Dreifuss JJ, Tribollet E: Binding sites for vasopressin in the human pituitary are associated with corticotrophs and may differ from other known vasopressin receptors. J Neuroendocrinol 1991, 3:237-247.
38. De Keyzer Y, Lenne F, Auzan C, Jegou S, René P, Vaudry H, Kuhn JM, Luton JP, Clauser E, Bertagna X: The pituitary vasopressin V3 receptor and the corticotroph phenotype in ectopic ACTH syndrome. J Clin Invest 1996, in press. The first study of V3 receptor gene expression in ACTH-secreting human tumors, RT-PCR, in situ hybridization, and S1 mapping with a genomic probe are used. The presence of the V3 receptor in bronchial carcinoids is associated with POMC-producing tumors and correlated with the in vivo responses to lysine-vasopressin.
39. Raux MC, Binoux M, Luton JP, Gourmelen M, Girard F: Studies of ACTH secretion control in 116 cases of Cushing's syndrome. J Clin Endocrinol Metab 1975, 40:186-197.
40. Hirata Y, Yamamoto H, Matsukura S, Imura H: In vitro release and biosynthesis of tumor ACTH in ectopic ACTH producing tumors. J Clin Endocrinol Metab 1975, 41:106-114.
41. De Keyzer Y, Bertagna X, Luton JP, Kahn A: Variable modes of proopiomelanocortin gene transcription in human tumors. Mol Endocrinol 1989, 3:215-223.
42. De Keyzer Y, Bertagna X, Lenne F, Girard F, Luton JP, Kahn A: Altered proopiomelanocortin gene expression in ACTH producing non-pituitary tumors. J Clin Invest 1985, 76:1892-1898.
43. Texier PL, De Keyzer Y, Lacave R, Vieau D, Lenne F, Rojas-Miranda A, Verley JM, Luton JP, Kahn A, Bertagna X: Proopiomelanocortin gene expression in normal and tumoral human lung. J Clin Endocrinol Metab 1991, 73:414-420.
44. Bertagna X: Proopiomelanocortin-derived peptides. Endocrinol Metab Clin North Am 1994, 23:467-485.
45. Phlipponneau M, Nocaudie M, Epelbaum J, De Keyzer Y, Lalau JD, Marchandise X, Bertagna X: Somatostatin analogs for the localization and preoperative treatment of an ACTH-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 1994, 78:20-24.
46. 2) in its normal site. Effects are obtained that do not need a ligand. There may be a role for inverse agonists.
47. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G: Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993, 365:649-651.
48. Utiger RD: Inappropriate antidiuresis and carcinoma of the lung: detection of arginine vasopressin in tumor extracts by immunoassay. J Clin Endocrinol Metab 1966, 26:970-974.
49. Becker KL: Historical perspective on the pulmonary endocrine cell. In The Endocrine Lung in Health and Disease. Edited by Becker KL, Gazdar AF. Philadelphia: W.B. Saunders; 1984:156-161.
50. Therrien M, Drouin J: Cell-specific helix-loop-helix factor required for pituitary expression of the pro-opiomelanocortin gene. Mol Cell Biol 1993, 130:2342-2353.
51. Gerrero MR, McEvilly RJ, Turner E, Lin CR, O'Connell S, Jenne KJ, Hobbs MV, Rosenfeld MG: Brn-3.0: a POU-domain protein expressed in the sensory, immune, and endocrine systems that functions on elements distinct from known octamer motifs. Proc Natl Acad Sci U S A 1993, 90:10841-10845.
52. Tremblay J, Lammonerie T, Lanctot C, Therrien M, Drouin J: A novel homeobox transcription factor is expressed in early pituitary development and is a major determinant for cell-specific transcription of the proopiomelanocortin gene [abstract]. Am Endocr Soc Washington 1995; 69.
53. Israel A, Cohen SN: Hormonally mediated negative regulation of human prop-opiomelanocortin gene expression after transfection into mouse L cells. Mol Cell Biol 1985, 5:2443-2453.
54. Picon A, Leblond-Francillard M, Raffin-Sanson ML, Lenne F, Bertagna X, De Keyzer Y: Functional analysis of the human proopiomelanocortin promoter in the small cell lung carcinoma cell line DMS 79. J Mol Endocrinol 1995, 15:187-194.
55. Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA: Neuroendocrine neoplasms of the bronchopulmonary tract A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg 1985, 89:819-825.
56. Stewart PM, Gibson S, Crosby SR, Penn R, Holder R, Ferry D, Thatcher N, Phillips P, London DR, White A: ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol 1994, 40:199-204.
57. Farrel WE, Clark AJL, Stewart MF, Crosby SR, White A: Bromocriptine inhibits Pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines. J Clin Invest 1992, 90:705-710.
58. White A, Clark A: The cellular and molecular basis of the ectopic ACTH syndrome. Clin Endocrinol 1993, 39:131-142.
59. Gaitan D, DeBold CR, Turney MK, Zhou PH, Orth DN, Kovacs WJ: Glucocorticoid receptor structure and function in an adrenocorticotropin-secreting small lung cancer. Mol Endocrinol 1995, 9:1193-1201. Finally, the molecular explanation for the glucocorticoid resistance of the POMC-producing human SCCL cell line DMS-79.